Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.

摘要: Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens. Background Parenteral iron are frequently required patients. However, serious adverse events have been reported after single doses some intravenous products. This multicenter phase IV clinical trial examined the safety for treatment deficiency sufficiency Methods In this study, was given two dosing deficient patients were treated with sucrose, 100 mg, during 10 consecutive sessions (replacement regimen). replete mg (iv) over 5 minutes, weekly weeks (maintenance At end each 10-dose cycle, status reassessed, subsequent cycle based on adequacy stores as per Dialysis Outcome Quality Initiative (K/DOQI) Guidelines. With regimen, events, if any, recorded described. Results Six hundred sixty-five patients, including 80 who had experienced previous intolerance to other parenteral preparations, received a total 8583 sucrose. One eighty-eight more than one iv (replacement, maintenance, or both). There no life-threatening drug-related events. Conclusion is safe when stores.